What is Esperion Therapeutics's net investment in lease?

Esperion Therapeutics (ESPR) reported net investment in lease of $2.7M in Q1 2026.

How has Esperion Therapeutics's net investment in lease changed year-over-year?

Esperion Therapeutics's net investment in lease decreased by 45.6% year-over-year, from $4.97M to $2.7M.

What is the long-term trend for Esperion Therapeutics's net investment in lease?

Over 5 years (2020 to 2025), Esperion Therapeutics's net investment in lease has grown at a -13.5% compound annual growth rate (CAGR), from $6.03M to $2.92M.

Esperion Therapeutics ESPR Net Investment in Lease

Net Investment in Lease at other companies

NewAmsterdam Pharma CompanyNAMS

——

Lexicon PharmaceuticalsLXRX

——

Zevra Therapeutics, Inc.ZVRA

——

Eton Pharmaceuticals, Inc.ETON

——

Nurix Therapeutics, Inc.NRIX

——

BridgeBio PharmaBBIO

——

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's net investment in lease?: Esperion Therapeutics (ESPR) reported net investment in lease of $2.7M in Q1 2026.
How has Esperion Therapeutics's net investment in lease changed year-over-year?: Esperion Therapeutics's net investment in lease decreased by 45.6% year-over-year, from $4.97M to $2.7M.
What is the long-term trend for Esperion Therapeutics's net investment in lease?: Over 5 years (2020 to 2025), Esperion Therapeutics's net investment in lease has grown at a -13.5% compound annual growth rate (CAGR), from $6.03M to $2.92M.